-
If the flu season hits your community hard, will your health care staff suffer because they didnt get enough flu shots? Quite possibly. But there is something risk managers can do.
-
Patient safety is on everyones minds these days, but how do you know how well your organization already is doing on this topic? One way is a tool offered by the Agency for Health-care Research and Quality (AHRQ), an arm of the Department of Health and Human Services in Washington, DC.
-
The management of heart disease has undergone a dramatic evolution over the past 20 years, driven by major developments in devices used for the treatment of vascular conditions and arrhythmia.
-
What precisely does innovation mean in the context of healthcare? Delos Toby Cosgrove, MD, the newly appointed president and CEO of the Cleveland Clinic, addressed that question in his opening remarks at this years Clinic-sponsored Medical Innovation Summit.
-
In late September, the fourth annual MedTec Ireland conference and trade show was held in the small but buzzing Irish city of Galway, sponsored by Canon Communications.
-
Sir George Alberti, head of emergency care for the UKs National Health Service (NHS), said that improvements in this area over the past two years have transformed its emergency care performance so that it is now the envy of the world. Speaking at a late-October breakfast reception at the home of Prime Minister Tony Blair, Alberti said that at the beginning of 2003, almost one-quarter of patients spent more than four hours in Accident and Emergency (A&E) units.
-
Thus far, the two drug-eluting stent (DES) products commercialized in the U.S. utilize a polymer as a method of incorporating drug and device. But the first-generation use of polymers may not be a model for future DES technologies, according to Martin Leon, MD, chairman of the Cardiovascular Research Institute (New York), in a presentation on the future of DES technologies during this years annual meeting of the American Heart Association (Dallas) in New Orleans.
-
Angiotech Pharmaceuticals (Vancouver, British Columbia) reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has expired pertaining to the proposed grant of an exclusive license to Boston Scientific (Natick, Massachusetts) with respect to the use of paclitaxel and other agents on medical devices in the coronary vascular field of use.
-
The annual scientific sessions of the American Heart Association (AHA; Dallas) primarily feature broad platforms for new product rollouts, an avalanche of clinical trials and even, occasionally, some interesting debate.
-
CryoCath Technologies (Montreal), a company developing cryotherapy products to treat cardiovascular disease, reported that its Freezor MAX catheter has received a supplemental premarket approval (PMA) indication from the FDA, allowing it to launch its fifth product into the U.S.
